menu
    • menu

    Company profile for Boehringer Ingelheim GmbH

    munit-sa-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The Boehringer Ingelheim group of companies objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim....
    The Boehringer Ingelheim group of companies objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Boehringer Ingelheim GmbHGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Corporate Division Communications, Binger Strasse 173, 55216 Ingelheim am Rhei...
    Telephone
    Telephone
    +49 - 6132 - 77 0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.boehringer-ingelheim.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/boehringer-ingelheim
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/boehringer

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 882

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    CDMO Activity Tracker: Axplora enhances ADC capacities, Quotient beefs up HPAPI capabilities; Evonik, EUROAPI forge deals

    CDMO Activity Tracker: Axplora enhances ADC capacities, Quotient beefs up HPAPI capabilities; Evonik, EUROAPI forge deals

    The contract development and manufacturing organization (CDMO) sector witnessed significant activity in the first quarter (Q1) of 2025, characterized by strategic investments, facility expansions, and collaborative partnerships.The quarter saw some significant deals. WuXi Biologics agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to Merck for € 500 million (US$  521 million). Quadria Capital announced the acquisition of a 10 percent stake in Aragen for US$ 100 million. This investment will help Aragen accelerate its research and development efforts.Some CDMOs, like India-based Syngene International and Belgium-based Ardena expanded their presence in the US market. Syngene completed the acquisition of its first US biologics facility that it had purchased from Emergent Manufacturing Operations Baltimore for US$ 36.5 million. And, leading nanomedicine developer Ardena purchased a drug manufacturing unit in New Jersey from Catalent.  View CDMO Activity Tracker for Q1 2025 (Free Excel Available) Axplora expands its ADC capacities; Quotient Sciences wraps up HPAPI unit upgradeThe antibody-drug conjugate (ADC) market saw considerable investments by CDMOs. Axplora expanded its commercial payload production capabilities at its Le Mans site in France, reinforcing its position as a leading player in ADC manufacturing. This expansion is part of the France 2030 program and builds on Axplora’s track record of supplying 40 percent of the world’s marketed ADCs and 50 percent of ADCs approved by the US Food and Drug Administration (FDA).Samsung Biologics said it will support a series of LigaChem Biosciences’ ADC programs at its new dedicated ADC facility. Similarly, Cerbios-Pharma announced significant enhancements to its ADC production capabilities. Cerbios also announced the expansion of its high potency active pharmaceutical ingredients (HPAPIs) production capabilities. On March 31, Cerbios-Pharma got acquired by Healthcare Advanced Synthesis, a leading developer of APIs, HPAPIs and anticancer compounds. Both these global players are based in Switzerland. Overall, HPAPIs saw significant investments. Quotient Sciences made headlines with the successful completion of a US$ 1.4 million project designed to improve high potency handling capabilities at its Philadelphia (US) facility. The initiative focused on upgrading infrastructure and implementing advanced safety protocols to manage HPAPIs more effectively.Polfa Tarchomin achieved significant milestones in enhancing its pharmaceutical manufacturing capabilities. The company successfully completed the site acceptance test (SAT) for its vial filling and packaging line at the Center for Development and Production of Highly Potent Drugs, ensuring full functionality and compliance with good manufacturing practice (GMP) standards.Additionally, Polfa Tarchomin is installing a high-tech, high-containment robotic ONCO LINE designed for aseptic production of highly potent pharmaceutical products, including lyophilisates and liquid formulations in vials and pre-filled syringes. Developed in collaboration with leading global suppliers, this line supports multiple packaging formats and comes with advanced systems. With an annual production capacity of up to 6 million units, this line will set a new benchmark in pharmaceutical manufacturing.In a significant development for analytical testing, SK Pharmteco launched an enhanced laboratory specifically designed for HPAPIs. The new facility is in California (US).  View CDMO Activity Tracker for Q1 2025 (Free Excel Available) Evonik expands RNA portfolio; Catalent to support Galapagos’ CAR-T therapy trialsThe success of mRNA vaccines and the growing interest in RNA therapeutics is luring CDMOs to rapidly expand their capabilities in this emerging area. Evonik, in collaboration with ST Pharm, announced plans to expand its portfolio of RNA and nucleic acid therapeutic services during Q1. The partnership enables Evonik to provide customized nucleic acids from ST Pharm alongside its portfolio of lipid and lipid nanoparticle (LNP) drug product development services.ReciBioPharm secured a grant from the Bill & Melinda Gates Foundation to advance RNA manufacturing technologies that meet FDA standards with a focus on improving access to RNA therapeutics in low- and middle-income countries.The cell and gene therapy sector also witnessed remarkable activity in Q1 2025. Catalent announced it will support Galapagos’ decentralized CAR T therapy trials for GLPG5101 for relapsed/refractory non-Hodgkin lymphoma indications.Similarly, AGC Biologics announced it will manufacture and supply lentiviral vectors for Adaptimmune’s solid tumor cell therapy initiatives. And, Genenta and AGC Biologics strengthened their cell therapy manufacturing pact through a collaboration agreement. This grants Genenta access to the exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to manufacturing cell therapy products.  View CDMO Activity Tracker for Q1 2025 (Free Excel Available) EUROAPI, StrainChem join hands to develop peptides; Fermion expands flow chemistry capabilitiesEven traditional therapeutics like peptides and small molecules saw considerable investments by CDMOs. For instance, EUROAPI and StrainChem announced a collaborative venture to develop liquid phase peptides. The partnership aims to harness advanced synthesis techniques and innovative technologies for more efficient peptide manufacturing. Through this collaboration, EUROAPI and StrainChem will offer their customers a one-stop shop solution for peptides. In one of the most ambitious expansions announced this quarter, CordenPharma unveiled plans to invest over € 1 billion (US$ 1.10 billion) over the next three years in building and expanding small, medium, and large peptide manufacturing facilities across Europe and the US. That includes a new greenfield facility for peptide manufacturing in the Basel region of Switzerland, valued at over € 500 million (US$ 553 million).In obesity treatments, Viking Therapeutics agreed to pay US$ 150 million to CordenPharma for the production of its dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) agonist VK2735.In a show of confidence, Indian CDMO Neuland Labs’ board approved a ₹ 3.42 billion (approximately US$ 42 million) capital expenditure plan. The approved capex is earmarked for enhancing the company’s peptide synthesizer reactor capacity and building additional capacity to meet growing demand.In the small molecule space, Fermion announced a strategic investment to expand its flow chemistry capabilities, aiming to enhance processes and sustainability by integrating continuous flow techniques into manufacturing. This technology offers advantages in scalability, process control, and safety, positioning Fermion at the forefront of pharmaceutical innovation.Recipharm announced a major expansion of its aseptic filling capabilities, encompassing process development, pilot-scale production, and clinical supply operations. Similarly, Curia announced significant expansions to its global network of sterile fill-finish sites, aiming to enhance production capacity, streamline supply chains, and improve overall quality in sterile pharmaceutical manufacturing.  View CDMO Activity Tracker for Q1 2025 (Free Excel Available) Our viewDuring Q1 2025, the CDMO sector continued to evolve towards higher-value and more complex services. This only underscores the crucial role CDMOs are playing in supporting growth and innovation in the pharmaceutical industry.With the Trump administration in the US triggering a global tariff war, drugmakers have no option but to reshape their supply chains. And this means more business for CDMOs that manufacture drugs in the US. In the coming quarter, we expect strong dealmaking and increased focus on innovation in the CDMO sector. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1703

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-axplora-enhances-adc-capacities-quotient-beefs-up-hpapi-capabilities-evonik-euroapi-forge-deals

    #PharmaFlow by PHARMACOMPASS
    10 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Salipro Biotech, Boehringer Ingelheim Partner to Accelerate Pipeline
    Salipro Biotech, Boehringer Ingelheim Partner to Accelerate Pipeline

    13 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/13/3042222/0/en/Salipro-Biotech-and-Boehringer-Ingelheim-Enter-Research-and-License-Agreement-to-Accelerate-Multiple-Boehringer-Ingelheim-Pipeline-Programs.html

    GLOBENEWSWIRE
    13 Mar 2025
    Share Share
    Cognizant and Boehringer Ingelheim Launch One Medicine Platform
    Cognizant and Boehringer Ingelheim Launch One Medicine Platform

    11 Mar 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/cognizant-and-boehringer-ingelheim-launch-one-medicine-platform/

    CONTRACTPHARMA
    11 Mar 2025
    Share Share
    Spevigo Data In GPP Patient Outcomes Presented At AAD 2025
    Spevigo Data In GPP Patient Outcomes Presented At AAD 2025

    07 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-analyses-on-the-potential-impact-of-spevigo-in-generalized-pustular-psoriasis-patient-reported-outcomes-presented-at-aad-2025-302395652.html

    PR NEWSWIRE
    07 Mar 2025
    Share Share
    Boehringer wins jury verdict in Zantac retrial in Illinois
    Boehringer wins jury verdict in Zantac retrial in Illinois

    26 Feb 2025

    // ENDPTS

    https://endpts.com/boehringer-ingelheim-wins-jury-verdict-in-zantac-retrial-in-illinois/

    ENDPTS
    26 Feb 2025
    Share Share
    CDR-Life Hits Fifth Milestone With Boehringer In Geographic Atrophy
    CDR-Life Hits Fifth Milestone With Boehringer In Geographic Atrophy

    25 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250225492391/en

    BUSINESSWIRE
    25 Feb 2025
    Share Share
    Boehringer Ingelheim launches new trivalent poultry vaccine
    Boehringer Ingelheim launches new trivalent poultry vaccine

    24 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/24/3030917/0/en/Boehringer-Ingelheim-launches-new-trivalent-poultry-vaccine-includes-protection-against-H5-avian-influenza.html

    GLOBENEWSWIRE
    24 Feb 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    OXB’s Technology to Support Boehringer’s Gene Therapy for Cystic Fibrosis

    Details:

    BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy designed to insert a functional copy of the CFTR gene in the DNA of airway epithelial cells for treating cystic fibrosis.


    Lead Product(s): BI 3720931

    Therapeutic Area: Genetic Disease Brand Name: BI 3720931

    Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Sponsor: OXB

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 20, 2025

    blank

    01

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BI 3720931

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : OXB

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    OXB’s Technology to Support Boehringer’s Gene Therapy for Cystic Fibrosis

    Details : BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy designed to insert a functional copy of the CFTR gene in the DNA of airway epithelial cells for treating cystic fibrosis.

    Product Name : BI 3720931

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    February 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zongertinib Receives Priority Review for HER2 (ERBB2)-mutant Advanced NSCLC

    Details:

    BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.


    Lead Product(s): Zongertinib

    Therapeutic Area: Oncology Brand Name: BI 1810631

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 19, 2025

    blank

    02

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Zongertinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Zongertinib Receives Priority Review for HER2 (ERBB2)-mutant Advanced NSCLC

    Details : BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.

    Product Name : BI 1810631

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Boehringer Widens Fibrosis Drug's Potential After 2nd Ph. 3 Win

    Details:

    BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for progressive pulmonary fibrosis.


    Lead Product(s): Nerandomilast

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BI 1015550

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 10, 2025

    blank

    03

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nerandomilast

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Boehringer Widens Fibrosis Drug's Potential After 2nd Ph. 3 Win

    Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for progressive pulmonary fibrosis.

    Product Name : BI 1015550

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Boehringer’s Nerandomilast Hits Primary Endpoint in Phase III FIBRONEER-ILD

    Details:

    BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for IPF.


    Lead Product(s): Nerandomilast

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BI 1015550

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 10, 2025

    blank

    04

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nerandomilast

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Boehringer’s Nerandomilast Hits Primary Endpoint in Phase III FIBRONEER-ILD

    Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for IPF.

    Product Name : BI 1015550

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

    Details:

    BI 425809(iclepertin), an investigational oral inhibitor of glycine transporter 1 (GlyT1), studied as a potential treatment for cognitive impairment in adults with schizophrenia.


    Lead Product(s): Iclepertin

    Therapeutic Area: Neurology Brand Name: BI 425809

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 16, 2025

    blank

    05

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iclepertin

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

    Details : BI 425809(iclepertin), an investigational oral inhibitor of glycine transporter 1 (GlyT1), studied as a potential treatment for cognitive impairment in adults with schizophrenia.

    Product Name : BI 425809

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 16, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Boehringer's Schizophrenia Drug Fails Trio of Phase 3 Trials

    Details:

    BI 425809 (iclepertin) is a glycine transporter 1 (GlyT1) inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with schizophrenia.


    Lead Product(s): Iclepertin

    Therapeutic Area: Psychiatry/Psychology Brand Name: BI 425809

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 16, 2025

    blank

    06

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iclepertin

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Boehringer's Schizophrenia Drug Fails Trio of Phase 3 Trials

    Details : BI 425809 (iclepertin) is a glycine transporter 1 (GlyT1) inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with schizophrenia.

    Product Name : BI 425809

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 16, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Malaysia Approves Spesolimab for Generalised Pustular Psoriasis Flares in Adults

    Details:

    Spevigo (spesolimab) is an IL-36 blocker, given by IV infusion, has been approved by CDSCO as the first treatment option for generalized pustular psoriasis flares in adults.


    Lead Product(s): Spesolimab

    Therapeutic Area: Dermatology Brand Name: Spevigo

    Study Phase: Approved FDFProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 13, 2024

    blank

    07

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Spesolimab

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Malaysia Approves Spesolimab for Generalised Pustular Psoriasis Flares in Adults

    Details : Spevigo (spesolimab) is an IL-36 blocker, given by IV infusion, has been approved by CDSCO as the first treatment option for generalized pustular psoriasis flares in adults.

    Product Name : Spevigo

    Product Type : Antibody

    Upfront Cash : Inapplicable

    December 13, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Torrent Pharma Inks Agreement with Boehringer Ingelheim to Acquire 3 Anti-Diabetes Brands

    Details:

    The acquisition strengthens Torrent’s existing diabetes portfolio by adding Cospiaq (empagliflozin), Cospiaq Met (empagliflozin & metformin) and Xilingio (empagliflozin & linagliptin) from Boehringer.


    Lead Product(s): Empagliflozin

    Therapeutic Area: Endocrinology Brand Name: Cospiaq

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Torrent Pharmaceuticals Limited

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition December 04, 2024

    blank

    08

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Empagliflozin

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Torrent Pharmaceuticals Limited

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Torrent Pharma Inks Agreement with Boehringer Ingelheim to Acquire 3 Anti-Diabetes Brands

    Details : The acquisition strengthens Torrent’s existing diabetes portfolio by adding Cospiaq (empagliflozin), Cospiaq Met (empagliflozin & metformin) and Xilingio (empagliflozin & linagliptin) from Boehringer.

    Product Name : Cospiaq

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    December 04, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Boehringer’s Nerandomilast Meets Primary Endpoint in FIBRONEER™-IPF Study

    Details:

    BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.


    Lead Product(s): Nerandomilast

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BI 1015550

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 16, 2024

    blank

    09

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nerandomilast

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Boehringer’s Nerandomilast Meets Primary Endpoint in FIBRONEER™-IPF Study

    Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.

    Product Name : BI 1015550

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 16, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Boehringer’s Zongertinib Shows Efficacy in HER2 Mutated Lung Cancer Patients

    Details:

    BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.


    Lead Product(s): Zongertinib

    Therapeutic Area: Oncology Brand Name: BI 1810631

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 09, 2024

    blank

    10

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Zongertinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Boehringer’s Zongertinib Shows Efficacy in HER2 Mutated Lung Cancer Patients

    Details : BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.

    Product Name : BI 1810631

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 09, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Boehringer Ingelheim GmbH and get a quotation

    Boehringer Ingelheim GmbH is a supplier offers 110 products (APIs, Excipients or Intermediates).

    Find a price of Epinastine Hydrochloride bulk with DMF, CEP, JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Ipratropium Bromide bulk with DMF, CEP, JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Repaglinide bulk with DMF, CEP, JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Digoxin bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Epinephrine bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Pramipexole Dihydrochloride bulk with DMF, CEP offered by Boehringer Ingelheim GmbH

    Find a price of Salbutamol Sulphate bulk with DMF, CEP offered by Boehringer Ingelheim GmbH

    Find a price of Scopolamine Hydrobromide bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Dipyridamole bulk with DMF offered by Boehringer Ingelheim GmbH

    Find a price of Hyoscine Butyl Bromide bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Tiotropium Bromide bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Atropine bulk offered by Boehringer Ingelheim GmbH

    Find a price of Atropine Sulfate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Brotizolam bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Clenbuterol Hydrochloride bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Clonidine bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Dihydroergotamine Mesylate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Epinephrine Bitartrate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Ergotamine Tartrate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Etilefrine bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Fenoterol Hydrobromide bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Homatropine Hydrobromide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Homatropine Methylbromide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Hyoscyamine Sulfate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Methocarbamol bulk with DMF offered by Boehringer Ingelheim GmbH

    Find a price of Methylphenidate Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Moxonidine bulk offered by Boehringer Ingelheim GmbH

    Find a price of Phenylephrine Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Pramipexole Dihydrochloride bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Scopolamine bulk offered by Boehringer Ingelheim GmbH

    Find a price of Tramazoline Hydrochloride Monohydrate bulk with CEP offered by Boehringer Ingelheim GmbH

    Find a price of Trospium Chloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Zolpidem Tartrate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Medium / Medium Additives / G-Medium bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Medium / Medium Additives-I-Medium bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Medium / Medium Additives ・ F-Media bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Medium / Medium Additives-P-Media bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Beperuminogen per plasmid bulk with JDMF offered by Boehringer Ingelheim GmbH

    Find a price of Amphetamine bulk offered by Boehringer Ingelheim GmbH

    Find a price of Beta-2 bulk offered by Boehringer Ingelheim GmbH

    Find a price of Brompheniramine Maleate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Caffeine bulk offered by Boehringer Ingelheim GmbH

    Find a price of Calcium Polycarbophil bulk offered by Boehringer Ingelheim GmbH

    Find a price of Camptothecine bulk offered by Boehringer Ingelheim GmbH

    Find a price of Crotamiton bulk offered by Boehringer Ingelheim GmbH

    Find a price of Dexrazoxane bulk offered by Boehringer Ingelheim GmbH

    Find a price of Digoxin bulk offered by Boehringer Ingelheim GmbH

    Find a price of Dihydroergotoxine Mesylate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Doxapram Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Esmolol Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Fentanyl bulk offered by Boehringer Ingelheim GmbH

    Find a price of Fentanyl Citrate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Glycopyrronium Bromide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Guaifenesin bulk offered by Boehringer Ingelheim GmbH

    Find a price of Isoproterenol Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of L-Lactide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Lanthanum Carbonate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Lobeline Sulfate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Meloxicam bulk offered by Boehringer Ingelheim GmbH

    Find a price of Metaproterenol Hemisulfate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Metaxalone bulk offered by Boehringer Ingelheim GmbH

    Find a price of Methadol Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Methadone Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Methscopolamine Bromide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Methscopolamine Nitrate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Metoclopramide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Milrinone bulk offered by Boehringer Ingelheim GmbH

    Find a price of Physostigmine Salicylate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Pilocarpine Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Ranitidine Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Scopolamine Hydrobromide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Theophylline bulk offered by Boehringer Ingelheim GmbH

    Find a price of Tiotropium Bromide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Yohimbine Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of PRODUCTION AND DISTRIBUTION FACILITY IN DANBURY, CONNECTICUT bulk offered by Boehringer Ingelheim GmbH

    Find a price of NR-LU-10 MURINE MONOCLONAL ANTIBODY FAB FRAGMENT (NOFETUMOMAB) AND PHENTHIOATE LIGAND BULK MATERIAL FOR ONCOTRAC KIT (NEORX) bulk offered by Boehringer Ingelheim GmbH

    Find a price of POLY-(D,L-LACTIDE-CO-GLYCOLIDE) 50:50 bulk offered by Boehringer Ingelheim GmbH

    Find a price of COPOLYMERS OF TRIMETHYLENE CARBONATE WITHL- OR D,L-LACTIDE bulk offered by Boehringer Ingelheim GmbH

    Find a price of rTNF-alpha Drug Substance bulk offered by Boehringer Ingelheim GmbH

    Find a price of IFN-OMEGA bulk offered by Boehringer Ingelheim GmbH

    Find a price of PHYSOSTIGMINE SALICYLATE (SYNTHETIC bulk offered by Boehringer Ingelheim GmbH

    Find a price of INTERLEUKIN-12 BULK SUBSTANCE bulk offered by Boehringer Ingelheim GmbH

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN RIDGEFIELD, CONNECTICUT. bulk offered by Boehringer Ingelheim GmbH

    Find a price of ESERETHOL bulk offered by Boehringer Ingelheim GmbH

    Find a price of Acepromazine bulk offered by Boehringer Ingelheim GmbH

    Find a price of Aldesleukin bulk offered by Boehringer Ingelheim GmbH

    Find a price of Alteplase bulk offered by Boehringer Ingelheim GmbH

    Find a price of Ampicillin bulk offered by Boehringer Ingelheim GmbH

    Find a price of Bromhexine Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Clenbuterol Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Dabigatran Etexilate Mesylate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Empagliflozin bulk offered by Boehringer Ingelheim GmbH

    Find a price of Firocoxib bulk offered by Boehringer Ingelheim GmbH

    Find a price of Interferon Beta 1B bulk offered by Boehringer Ingelheim GmbH

    Find a price of Linagliptin bulk offered by Boehringer Ingelheim GmbH

    Find a price of Moxetumomab Pasudotox bulk offered by Boehringer Ingelheim GmbH

    Find a price of Nintedanib Esylate bulk offered by Boehringer Ingelheim GmbH

    Find a price of Olodaterol Hydrochloride bulk offered by Boehringer Ingelheim GmbH

    Find a price of Penethamate Hydriodide bulk offered by Boehringer Ingelheim GmbH

    Find a price of Pimobendan bulk offered by Boehringer Ingelheim GmbH

    Find a price of Tafasitamab bulk offered by Boehringer Ingelheim GmbH

    Find a price of Tenecteplase bulk offered by Boehringer Ingelheim GmbH

    Find a price of Tipranavir bulk offered by Boehringer Ingelheim GmbH

    Find a price of Tylosin bulk offered by Boehringer Ingelheim GmbH

    Find a price of Apatinib maleate bulk offered by Boehringer Ingelheim GmbH

    Find a price of MANUFACTURING OPERATIONS bulk offered by Boehringer Ingelheim GmbH

    Find a price of ML-3,314,163 bulk offered by Boehringer Ingelheim GmbH

    Find a price of Nintedanib esilate bulk offered by Boehringer Ingelheim GmbH

    Find a price of INTERFERON BETA-1B bulk offered by Boehringer Ingelheim GmbH

    Find a price of Linagliptin (undifferentiated) bulk offered by Boehringer Ingelheim GmbH

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search